Long COVID: A Case Report of Long SARS-CoV-2 for One Year

Negar Mottaghi-Dastjerdi; Mahdi Yadollahzadeh; Maryam Farasatinasab; Hamid Owliaey; Marjan Shariatpanahi

doi:10.2174/0126667975286263240321050916

ISSN: 2666-7967
E-ISSN: 2666-7975

Long COVID: A Case Report of Long SARS-CoV-2 for One Year
Authors: Negar Mottaghi-Dastjerdi¹, Mahdi Yadollahzadeh², Maryam Farasatinasab³, Hamid Owliaey⁴ and Marjan Shariatpanahi^5,6
View Affiliations Hide Affiliations

¹ Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran ; ² Department of Internal Medicine, School of Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran ; ³ Department of Clinical Pharmacy and Pharmacoeconomics, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran ; ⁴ Department of Forensic Medicine & Clinical Toxicology, Islamic Azad University, Yazd Branch, Yazd, Iran ; ⁵ Department of Pharmacology and Toxicology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran ; ⁶ Neuroscience Research Center (NRC), Iran University of Medical Sciences, Tehran, Iran
Source: Coronaviruses, Volume 6, Issue 2, Jun 2025, e250324228303
DOI: https://doi.org/10.2174/0126667975286263240321050916
- Received: 08 Oct 2023
- Accepted: 05 Mar 2024
- Available online: 25 Mar 2024

Abstract

Introduction

‘Long COVID’ describes a wide range of symptoms lasting for at least four weeks after infection. Still, there are no therapies available right now that are intended to treat long-term COVID-19.

Case Presentation

Here, we reported a 36-year-old woman with 2 main issues: persistent symptoms for nine months after SARS-CoV-2 infection and selected symptoms after Sinopharm COVID-19 vaccination. In this case, after the third infection, severe fatigue, panic attacks and dermatological problems were permanent for approximately nine months. As there was no alternative diagnosis, she was diagnosed with ’long COVID’, and it is the longest duration recorded, as per our knowledge. Besides, 60 days after the second vaccination, pain in the calcaneus region of her left foot, mild chest pain, joint pain, severe shoulder pain, extreme fatigue, and numbness were among the reported symptoms.

Conclusion

Although these uncommon complications can be related to vaccination, the advantages of obtaining the vaccine exceed the risks.

Article metrics loading...

/content/journals/covid/10.2174/0126667975286263240321050916

2024-03-25

2025-07-13

From This Site

/content/journals/covid/10.2174/0126667975286263240321050916

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

References

TaribagilP. CreerD. TahirH. ‘Long COVID’ syndrome.BMJ Case Rep.2021144e24148510.1136/bcr‑2020‑241485 33875508
[Google Scholar]
SinghV. MishraV. Coronavirus disease 2019 (COVID-19): Current situation and therapeutic options.Coronaviruses2021248149110.2174/2666796701999201005211854
[Google Scholar]
SinghN. RaiS.N. SinghV. SinghM.P. Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.J. Chem. Neuroanat.202011010187410.1016/j.jchemneu.2020.101874 33091590
[Google Scholar]
McMahonD.E. GallmanA.E. HruzaG.J. Long COVID in the skin: A registry analysis of COVID-19 dermatological duration.Lancet Infect. Dis.202121331331410.1016/S1473‑3099(20)30986‑5 33460566
[Google Scholar]
OmololuA OjeladeB AjayiO Long COVID”: A case report of persistent symptoms in a patient with prolonged SARSCoV- 2 shedding for over 110 days.SAGE Open Med Case Rep202192050313X21101549410.1177/2050313X211015494
[Google Scholar]
BhaiyatA.M. SassonE. WangZ. Hyperbaric oxygen treatment for long coronavirus disease-19: A case report.J. Med. Case Rep.20221618010.1186/s13256‑022‑03287‑w 35168680
[Google Scholar]
SaeedB.Q. ShahrabiA.R. AlhajS.S. AlkokhardiZ.M. AdreesA.O. Side effects and perceptions following Sinopharm COVID-19 vaccination.Int. J. Infect. Dis.202111121922610.1016/j.ijid.2021.08.013 34384899
[Google Scholar]
Evidence assessment: Sinopharm/BBIBP COVID-19 vaccine.2021Available from: https://cdn.who.int/media/docs/default source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf (Accessed on: July 16, 2022).
ThaweethaiT. JolleyS.E. KarlsonE.W. Development of a definition of postacute sequelae of SARS-CoV-2 infection.JAMA2023329221934194610.1001/jama.2023.8823 37278994
[Google Scholar]
LeonL.S. OstroskyW.T. PerelmanC. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis.Sci. Rep.20211111614410.1038/s41598‑021‑95565‑8 34373540
[Google Scholar]
13 deaths and 12 cases of severe side effects after 8.2m Sinopharm inoculations.2021Available from: https://www.thaipbsworld.com/13-deaths-and-12-cases-of-severe-side-effects-after-8-2m-sinopharm-inoculations/ (Accessed on: July 16, 2022).
HSA’s safety update #6 COVID-19 vaccines.2021Available from: https://www.hsa.gov.sg/docs/default-source/hprg-vcb/safety-update-on-covid19-vaccines/hsa-safety-update-no-6-on-covid-19-vaccines-(30-sep-2021).pdf (Accessed on: July 16, 2022).
DavisH.E. McCorkellL. VogelJ.M. TopolE.J. Long COVID: Major findings, mechanisms and recommendations.Nat. Rev. Microbiol.202321313314610.1038/s41579‑022‑00846‑2 36639608
[Google Scholar]
TriantafyllidisK.K. GiannosP. MianI.T. KyrtsonisG. KechagiasK.S. Varicella zoster virus reactivation following COVID-19 vaccination: A systematic review of case reports.Vaccines 202199101310.3390/vaccines9091013 34579250
[Google Scholar]
PolackF.P. ThomasS.J. KitchinN. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.N. Engl. J. Med.2020383272603261510.1056/NEJMoa2034577 33301246
[Google Scholar]